The USC Norris Comprehensive Cancer Center at the University of Southern California was founded in 1971 and has been continuously supported by a Cancer Center Support Grant since 1973. It has developed into a major regional and national resource for cancer research, treatment, prevention and education. Center facilities have been built and developed with support from the NCI, the University and the Kenneth Norris Jr. Cancer Hospital, which is an integral part of the Cancer Center. The Center underwent a major expansion with the addition of the Norman Topping Tower in 1996 and the Harlyne Norris Research Tower in 2007. The Center's 198 members are organized into five thematic and five translational research programs, including a "bridge" program in developmental therapeutics. The thematic programs are headed by senior investigators in the fields of molecular genetics, epigenetics and regulation, tumor microenvironment, cancer epidemiology and cancer control research. The translational programs, which provide focus to our transdisciplinary research efforts, are in developmental therapeutics, genitourinary cancers, gastrointestinal cancers, women's cancers and leukemia and lymphoma. This application is for: 1) partial salary support for the Center's senior leadership, who are responsible for planning and overseeing our research efforts;2) support for program planning and evaluation to keep the Center at the forefront of cancer research;3) support for the administrative infrastructure of the Center;4) partial support for the Center's 11 shared resources which facilitate the conduct of our peer-reviewed research;and 5) support for developmental funds to help us recruit new investigators in areas we have targeted for expansion and to fund innovative pilot projects. Continued funding from the Cancer Center Core Support Grant will allow us to build on our strengths in basic and population-based research and to translate our underlying expertise into strong, peer-reviewed funded research programs focused on cancers of major consequence in this country. Cancer Center members currently hold grants totaling $125 million in direct costs, with $43 million of that coming from NCI (all exclusive of the CCSG).
The USC Norris Comprehensive Cancer Center provides the infrastructure and resources to facilitate and foster translational research for the development of more effective prevention, diagnosis, treatment of cancer.
|Gopalakrishnan, R; Matta, H; Tolani, B et al. (2016) Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 35:1797-810|
|Zeng, Chenjie; Matsuda, Koichi; Jia, Wei-Hua et al. (2016) Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk. Gastroenterology 150:1633-45|
|Fanini, Francesca; Fabbri, Muller (2016) Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art. Semin Cell Dev Biol :|
|Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56|
|Liu, Jie; Siegmund, Kimberly D (2016) An evaluation of processing methods for HumanMethylation450 BeadChip data. BMC Genomics 17:469|
|Taylor, Nicholas J; Thomas, Nancy E; Anton-Culver, Hoda et al. (2016) Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma. Int J Cancer 139:1217-22|
|Pulido, Mario A; DerHartunian, Meleeneh Kazarian; Sehgal, Prerna et al. (2016) Data on isoaspartylation of neuronal ELAVL proteins. Data Brief 9:1052-1055|
|Pannunzio, Nicholas R; Lieber, Michael R (2016) RNA Polymerase Collision versus DNA Structural Distortion: Twists and Turns Can Cause Break Failure. Mol Cell 62:327-34|
|(2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64|
|Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :|
Showing the most recent 10 out of 635 publications